Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Is the Parsimonious Eurolung risk model a good predictor for all populations? An external validation study
0
Zitationen
4
Autoren
2025
Jahr
Abstract
External validation was partially achieved. The Parsimonious Eurolung 1 score is moderately applicable for morbidity. The Parsimonious Eurolung 2 score is not validated for 30-day mortality in this cohort. It should not guide surgical eligibility, and this point can be generalized to other low-mortality settings. This study provides valuable insights into the performance of the Parsimonious Eurolung models in a specific national context while highlighting the ongoing challenges in risk prediction for thoracic surgery. The findings suggest a need for quality multicentric databases and more granular, population-specific risk models, potentially incorporating machine learning approaches.
Ähnliche Arbeiten
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
2011 · 10.745 Zit.
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 · 9.884 Zit.
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 · 8.195 Zit.
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
2015 · 6.473 Zit.
Deep Convolutional Neural Networks for Computer-Aided Detection: CNN Architectures, Dataset Characteristics and Transfer Learning
2016 · 5.682 Zit.